Pharmacological Modulation of Vagal Nerve Activity in Cardiovascular Diseases

Longzhu Liu¹ · Ming Zhao¹ · Xiaojiang Yu¹ · Weijin Zang¹

Abstract Cardiovascular diseases are life-threatening illnesses with high morbidity and mortality. Suppressed vagal (parasympathetic) activity and increased sympathetic activity are involved in these diseases. Currently, pharmacological interventions primarily aim to inhibit overexcitation of sympathetic nerves, while vagal modulation has been largely neglected. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients. Therefore, the improvement of vagal activity may be an alternate approach for the treatment of cardiovascular diseases. However, drugs used for vagus nerve activation in cardiovascular diseases are limited in the clinic. In this review, we provide an overview of the potential drug targets for modulating vagal nerve activation, including muscarinic, and β-adrenergic receptors. In addition, vagomimetic drugs (such as choline, acetylcholine, and pyridostigmine) and the mechanism underlying their cardiovascular protective effects are also discussed.

Keywords Cardiovascular disease · Cholinergic drugs · Muscarinic receptor · α7-nACh receptor · Vagus nerve · Vagomimetic drugs

Introduction

The vagus nerve, which is the longest cranial nerve in the human body, innervates the thoracic and abdominal organs, including the autonomic, cardiovascular, respiratory, gastrointestinal, immune, and endocrine systems. The vagus nerve is a key component of the autonomic nervous system (ANS) containing 80% afferent and 20% efferent nerve fibers [1]. The vagal afferent fibers sense a range of stimuli, including pressure, pain, stretch, temperature, chemicals, osmotic pressure, and inflammation. These sensory signals are gathered at the vagal nuclei and are transmitted to multiple brain regions. After being processed in the brain, regulatory signals are transmitted by the vagal efferent fibers. Vagal efferent fibers, which arise from the nucleus ambiguus and the dorsal motor nucleus, are primarily cholinergic, using acetylcholine (ACh) as their major neurotransmitter. Imbalances in the ANS, which are characterized by a reduction in vagal tone accompanied by increased sympathetic activity, are associated with disease progression and negative clinical outcomes, triggering many cardiovascular diseases, such as heart failure [2], arrhythmia [3] and hypertension [4]. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients [5–8]. However, the roles of drugs that activate vagal nerves and vagomimetic drugs in the treatment of cardiovascular disease are still not fully understood.

In the present review, we summarize the recent studies detailing the drugs used in vagal nerve activation for the treatment of cardiovascular disease, as well as putative mechanisms underlying the cardiovascular protective effects of these compounds.
Alteration of Vagal Tone in Cardiovascular Disease

The heart is dominated by both sympathetic and parasympathetic (vagal) nerves. The innervation by sympathetic and vagal nerves is asymmetrical. The right sympathetic and vagal nerves innervating the sinus node and atrium, primarily control the heart rate; the left sympathetic and vagal nerves innervating the atroventricular junction and the left ventricle, primarily control myocardial contractility and cardiac output [9]. The vagus nerve plays a vital role in maintaining normal cardiovascular function. Under physiological conditions, the sympathetic and parasympathetic (vagal) activities modulating cardiac function undergo a reciprocal regulation, leading to sympathovagal balance [10]. The sympathetic neurotransmitter catecholamine is released, which increases the heart rate and myocardial contractility [11]. Simultaneously, the vagal nerve releases ACh to reduce the conduction of pacemaker cells in the sinus node, thereby lowering the heart rate and the myocardial contractility [12]. Under pathological conditions, autonomic imbalance and increased cardiac sympathetic nerve activity lead to an increased heart rate, increased myocardial contractility, and increased myocardial oxygen consumption. Meanwhile, decreased vagal nerve discharge and a decrease in the amount of ACh released into the synaptic cleft, lead to the loss of the ability of the vagal nerve to reduce the heart rate and decrease myocardial contractility. Ultimately, this loss results in cardiac overload and enhanced cardiovascular damage [4]. Thus, the restoration or enhancement of vagal nerve activity may be a promising therapy for cardiovascular disease.

The activation of vagal nerves occurs at multiple levels, including the afferent, central, and efferent components and all related effectors. Our primary concern is the relationship between activation of the vagal efferent component and cardiovascular disease. Vagal efferents can be activated during the following processes: (1) an increase in neuronal discharge and ACh release by activation of the central axis and direct vagal nerve stimulation; (2) the administration of cholinergic drugs or the indirect increase in ACh levels by administration of cholinesterase inhibitors; and (3) an increase in ACh bioavailability by activation of the ACh-associated receptors (M receptors and the N receptor) and downstream pathways.

Although many methods can be used to study vagal activity in experiments, only heart rate variability (HRV) and baroreflex sensitivity (BRS) are commonly used in the clinic [13]. HRV and BRS are important markers that are typically used to indirectly assess vagal activity [14–21]. BRS is primarily regarded as a measure of vagal reflex activity and is expressed in milliseconds of increase in the RR interval consequent to an increase of 1 mmHg in blood pressure [22]. HRV is the variation over time of the period between consecutive heartbeats [23]. Other methods, such as the ACh level in the blood measured by microdialysis [6], cardiac automatic nerves and cholinergic nerve distribution by immunohistochemistry [24], autonomic tone and intrinsic heart rate by administration of atropine and propranolol [25, 26] or neuronal/vagal discharge measured by a biological signal analytical system [27], can also be used to evaluate vagal activity in experiments (Fig. 1).

Decreased Vagal Tone is Associated with Increased Mortality in Heart Failure

Heart failure (HF) is a leading cause of morbidity and mortality. The ANS plays an important role in regulating pathological cardiac remodeling in HF. An imbalance in the ANS is a predictor for a negative prognosis in patients with HF. It has been demonstrated that decreased vagal tone is associated with an increase in mortality for HF [28]. A recent report indicates that the neurotransmitter response of the cardiac vagal neurons in the brain stem is altered [29]. The sympathovagal imbalance often results in left ventricular dysfunction during the early stages of HF [30]. Decreased ventricular epicardial vagal nerve density has also been reported to potentially contribute to impaired cardiac vagal control in rats with HF [31]. For the treatment of HF, vagus nerve stimulation (VNS) has been shown to be beneficial for improving the autonomic balance in HF by enhancing vagal tone [32]. A recent report has also shown that short-term intravenous VNS markedly reduces infarct size and prevents subsequent HF. The bradycardic effect may play an important role in the beneficial effect of VNS [33].

Arrhythmia with Reduced Vagal Tone after Myocardial Infarction

Many studies have indicated that the ANS plays a pivotal role in the development of arrhythmias [34–36]. Electrical wave-break-induced re-entry can cause the onset of arrhythmia. Wave-break is primarily affected by two factors. Anatomical factors, such as scars and fibrosis, affect wave-break and lead to tissue heterogeneity and electrical remodeling. Changes in membrane voltage and intracellular Ca2+ levels also affect wave-break. Arrhythmia with reduced vagal tone after myocardial infarction is a life-threatening risk factor [13]. We have reported that cholinergic nerves and M2 receptors are located in both rat atria and ventricles [37]. Inagaki et al. have found that
VNS reduces the rate of ventricular fibrillation from 62% to 7% in cats [38]. Over the years, VNS has been shown not only to slow down the sinus rate but also to display many beneficial effects that protect the heart against ventricular arrhythmias, including decreased heart rate, reduced atrioventricular conduction, and reduced atrial contraction [39]. Vagal modulation plays a significant role in the initiation and development of arrhythmias, and novel vagomimetic drug discovery may hold the key to treatment.

Reduced Vagal Activity Contributes to Hypertensive Organ Damage

The ANS plays a critical role in maintaining cardiovascular homeostasis during hypertension. Vagal nerve fibers can modulate local and systemic inflammatory responses, known as the ‘cholinergic anti-inflammatory pathway’ [40]. Both a decrease in ACh release and dysfunction of the α7 nicotinic ACh receptor contribute to hypertensive organ damage. Recently, chronic VNS has been reported to prevent hypertension-induced endothelial dysfunction and aortic stiffening in spontaneously hypertensive rats (SHRs) [41]. Our group also demonstrated that an increase in the expression of TLR4 and pro-inflammatory cytokines may be correlated with suppressed vagal activity in SHRs [16]. Therefore, increasing vagal activity may be an interesting alternative approach for antihypertensive therapy.

Abnormal ANS activity is correlated with many other cardiovascular diseases, such as myocardial infarction [42], ischemia/reperfusion injury [43], and atherosclerosis [44]. In summary, the vagal nerve plays an important role in many cardiovascular diseases, and further investigation is required to find therapies for restoring impaired vagal nerve function to improve clinical outcomes and prognoses.

Fig. 1 Methods and indices used to evaluate vagal activity in cardiovascular disease. Vagus activity can be evaluated by (I) measurement of the vagal discharge (image adapted from Lu Y et al. [27]); (II) autonomic tone and intrinsic heart rate; (III) HRV and BRS; (IV) cardiac autonomic nerves and cholinergic nerve distribution; and (V) detection of the release of ACh into the circulation (image adapted from Zhao M et al. [6]). ACh, acetylcholine; BRS, baroreflex sensitivity; HPLC, high performance liquid chromatography; HRV, heart rate variability; PSYM, parasympathetic; SYM, sympathetic.
Potential Targets for Vagal Nerve Activation in Cardiovascular Disease

Muscarinic Receptors and Cardiovascular Diseases

Cholinergic receptors are conventionally divided into two types of ACh receptors (AChRs), namely, the muscarinic and nicotinic receptors. The muscarinic ACh receptor (mAChR) is a member of a sub-family of G protein-coupled receptors that includes the M1–M5 subtypes [45]. These mAChRs exist in many tissues and cells, acting under the control of parasympathetic innervation. Among these mAChRs, the M2 and M3 receptor subtypes are important in the cardiovascular system. Previous studies have shown that the M2 receptor is primarily distributed in myocardial cells [46]. Our studies have also shown that ACh inhibits tumor necrosis factor alpha production by downregulating p38 mitogen-activated protein kinase (MAPK) and JNK phosphorylation; this is mediated by the M2 receptor, and M2 antagonists or the knockdown of M2 receptor expression by siRNA abolishes the effects of ACh-induced protection in cardiomyocytes [47, 48]. Recent studies have found that the M3 receptor subtype is also distributed in myocardial cells [49], and plays a protective role in cardiovascular disease [50]. Some studies have reported that M3 receptor activation reduces angiotensin II-induced cardiac hypertrophy, corrects cardiac hemodynamic dysfunction, inhibits myocardial cell apoptosis, and reduces myocardial injury [51]. A recent study indicated that activation of the M3 receptor by VNS improves mitochondrial dynamics and mitochondrial function in isoproterenol-induced myocardial ischemia [52]. The pharmacological activation of M3 receptors also has a cardioprotective effect in ischemia-induced ischemia/reperfusion (I/R) injury [7]. Furthermore, the over-expression of M3 receptors decreases the incidence of arrhythmias in a mouse model of myocardial I/R injury [53].

Nicotinic Acetylcholine Receptors and Cardiovascular Diseases

Nicotinic ACh receptors (nAChRs) are ion channels formed by five subunits delimiting a central aqueous pore. nAChRs have been identified in many cell types, including vascular smooth muscle cells [54] and endothelial cells [55]. nAChRs have been suggested to be involved in the cardioprotection conferred by vagal nerve stimulation [14]. In particular, the primary function of the α7nAChR subtype in mediating this inflammatory response is now well-accepted [56]. ACh binds to the α7nAChR, which inhibits the transcriptional activity of p38 MAPK and nuclear factor-kappa B [57]. Furthermore, α7nAchR activation can also recruit Janus kinase 2 (Jak2) to form a heterodimeric complex, initiating an intracellular transduction response mediated by signal transducer and activator of transcription 3 (STAT3) [58]. Vagal stimulation protects against myocardial I/R-induced remote vascular dysfunction through the cholinergic anti-inflammatory pathway, which is dependent upon α7nACh receptors [6]. Previous studies have also shown that α7nACh receptors block inflammasome complex activation by suppressing mitochondrial DNA release [59]. Therefore, the pharmacological activation of α7nAchR, by improving vagal activity, characterizes an alternative approach for treating cardiovascular disease.

β2 Adrenergic Receptors and Cardiovascular Disease

Adrenergic receptors (ARs) are a large family of seven-transmembrane domain receptors responsive to catecholamines. ACh released by the vagus nerve in the celiac mesenteric ganglia activates the splenic nerve through postsynaptic α7nAchRs [60]. Then, noradrenaline released from splenic nerve terminals promotes β2AR activation in T cells in the spleen [61]. The β2AR-activated T cells then produce ACh, which activates α7nAchRs on cytokine-producing macrophages, thus inhibiting the release of cytokines from the spleen [62]. These studies have indicated that β2AR-activated T cells in the spleen are critical for the anti-inflammatory action of the vagus nerve [63], and β2ARs represent a potential pharmacological target for vagal activation in cardiovascular disease.

Drugs for Cardioprotection by Vagal Nerve Activation

Modulation of the vagal nerve activity is theoretically a promising therapy for cardiovascular disease. Current, major, non-drug-activated vagal nerve activation approaches include direct vagal stimulation through surgically implanted stimulators [64], and indirect renal sympathectomy [65], aerobic exercise, and yoga [66]. At present, VNS has been clinically applied in patients with drug-resistant epilepsy, depression, and heart failure. VNS has also been found to have a protective effect against myocardial infarction-induced arrhythmias, inhibit the abnormal ventricular electrophysiological changes that can be induced by sympathetic over-activation, and reduce the incidence of heart fibrillation [64].

Although there is already much evidence that direct VNS can effectively improve the occurrence and development of cardiovascular disease [52, 64], due to surgical trauma, poor patient compliance, and an inadequate
response in patients with cardiac insufficiency, its widespread application in the clinic has been limited. Therefore, activation of the vagus nerve by pharmacological tools may be another option for patients with cardiovascular disease as an alternative to direct VNS. The primary drug targets used for vagal nerve activation in cardiovascular diseases have included: (1) vagomimetic agents that directly increase the levels of synaptic ACh to activate muscarinic and nicotinic receptors; (2) cholinesterase inhibitors that indirectly decrease the degradation of ACh; and (3) adenosine, statins, beta-receptor blockers and angiotensin-converting-enzyme inhibitors (ACEIs), which also indirectly activate vagal tone; however, the underlying mechanisms through which these drugs stimulate vagal activation still require further investigation (Fig. 2).

### Cholinergic Drugs Used in the Treatment of Cardiovascular Diseases

#### Choline

The essential nutrient choline participates in various biological processes. It is a component of two biologically important molecules, phosphatidylcholine and ACh. Choline has been used in the clinical treatment of steatohepatitis [73]. Accumulating evidence has demonstrated that choline also has multiple protective effects against various cardiovascular diseases, including myocardial infarction [42], arrhythmias [74], cardiac hypertrophy [75, 76], and I/R injury [77]. Choline has also been demonstrated to have a protective effect against vascular damage in rats after I/R through the inhibition of the reactive oxygen species (ROS)-mediated Ca\(^{2+}\)/calmodulin-dependent protein kinase II (CaMKII) pathway and the regulation of Ca\(^{2+}\) cycling proteins. These protective effects may be attributed to activation of the M3 receptor [7]. Recently, our group

---

**Fig. 2** Schematic of the drug targets for vagal nerve activation. 

- **A. Cholinergic drugs** (e.g., Choline Acetylcholine)
  - Choline is synthesized *in vivo* by the catalysis of choline and acetyl-CoA by choline acetyltransferase, thus directly increasing the levels of synaptic ACh [67].

- **B. AChE inhibitors**
  - Cholinesterase inhibitors increase the levels of synaptic ACh by decreasing its degradation, and thus directly increasing vagal tone [68].

- **C. Other drugs** (e.g., adenosine, statins, β-receptor blockers)
  - Adenosine [69], statins [70], beta-receptor blockers [71], and ACEIs [72] indirectly activate vagal tone by acting on the related receptors. Acetyl-CoA, Acetyl-coenzyme A; AChE, acetylcholine esterase; ACEIs, angiotensin-converting-enzyme inhibitors; ACh, acetylcholine.
demonstrated that choline slows the progress of hypertension and ameliorates cardiac, renal, and vascular damage in SHRs. These protective effects may be related to the improvement in vagal activity and the reduction in inflammatory cytokines found in SHRs [16]. These studies indicate that choline may be a promising therapeutic agent for the alleviation of cardiovascular damage in cardiovascular disease, although the mechanisms underlying its cardiovascular protective effects require further investigation.

Acetylcholine

ACh is the endogenous agonist for the two primary types of cholinoreceptor, the muscarinic and nicotinic receptors and they will likely become novel targets for drug development [78]. In vivo microdialysis studies have demonstrated that vagal stimulation increases the ACh concentration in the mesenteric circulation, suggesting that the ACh released from the vagus nerve is transported into the mesenteric circulation and has effects on endothelial cells and vascular smooth muscle cells [6]. Studies in our laboratory have demonstrated that ACh prevents angiotensin II-induced cardiomyocyte injury through down-regulation of the angiotensin II type 1 receptor and inhibition of ROS-mediated p38 MAPK activation, as well as regulation of Bcl-2, Bax, and caspase-3 expression [48, 79–81]. Recently, we demonstrated that ACh markedly suppresses the mitochondrial unfolded protein response and endoplasmic reticulum stress, which alleviate I/R injury [82, 83]. ACh may also modulate the abnormal inter-organelle crosstalk in cardiovascular diseases. Our studies indicated that ACh attenuates intracellular Ca\(^{2+}\) overload by inhibiting the formation of the VDAC1/Grp75/IP3R1 complex and the NCX1-TRPC3-IP3R1 complex in mitochondria-endoplasmic reticulum and endoplasmic reticulum-plasma membrane connection sites in human umbilical vein endothelial cells, indicating that the inhibition of inter-organelle crosstalk may be a mechanism for vagal protective effects in cardiovascular disease [84, 85]. Currently, ACh is primarily used as a pharmaceutical tool due to the multiple effects that it has throughout the body.

Acetylcholinesterase Inhibitors for the Treatment of Cardiovascular Disease

Pyridostigmine

There are two types of cholinesterase inhibitors: reversible anticholinesterase and irreversible cholinesterase inhibitors. Irreversible cholinesterase inhibitors are used as organic pesticides and are highly toxic, while reversible anticholinesterases have relatively lower toxicity. Peripheral reversible acetylcholinesterase inhibitors such as pyridostigmine bromide (PYR) have been used for the clinical treatment of myasthenia gravis and chronic heart failure [86, 87]. In addition, the development of new delivery methods (e.g., liposomes and nanoparticles) may reduce the side-effects of PYR [88, 89]. Evidence has shown that long-term treatment with PYR increases cardiac vagal tone, reduces sympathetic tone, and attenuates cardiac remodeling and left ventricular dysfunction during the progress of HF in mice [90]. More recent studies have demonstrated important roles for PYR in preserving autonomic balance [91, 92]. Our studies have also suggested that PYR restores baroreflex sensitivity, improves HRV, inhibits renin-angiotensin-system (RAS) activation and suppresses angiotensin II-induced cardiac fibroblast activation, thus ameliorating cardiac remodeling and improving peripheral vascular endothelial function in rats with myocardial infarctions or abdominal aortic constriction [17, 27, 93, 94]. These data support the notion that the enhancement of vagal tone by PYR is beneficial during cardiovascular disease. Seven days of PYR treatment has been demonstrated to improve intrinsic heart rate and autonomic tone, while reducing the area of myocardial infarction [95]. Yu et al. [96] have demonstrated that PYR treatment increases capillary density after myocardial infarction in rats. In addition, Durand et al. [97] have concluded that the immediate administration of this drug after myocardial infarction is an important pharmacological intervention to protect against potentially negative changes in cardiac autonomic imbalance. A recent report also indicated that PYR associated with exercise training benefits cardiovascular autonomic modulation and reduces inflammatory responses in infarcted rats [98]. Chronic treatment with PYR or donepezil increases cardiac vagal tone, reduces cardiomyocyte diameter, collagen density, and inflammatory cytokine levels in the plasma of SHRs [99]. Thus, the administration of acetylcholinesterase inhibitors may pharmacologically mimic activation of the cholinergic system, and contribute to cytokine production and the amelioration of myocardial infarction. The most recent study also demonstrated that the administration of PYR for 12 weeks ameliorates the cardiomyopathy induced by a high-fat diet in Sprague-Dawley rats, which is accompanied by improved vagal activity, reduced cardiac lipid accumulation, and the facilitated browning of white adipose tissue while activating brown adipose tissue [100]. However, studies are still necessary to better understand the pleiotropic effects of PYR on cardiovascular protection.
Other Drugs for Cardiovascular Protection (Adenosine, Statins, β-Receptor Blockers, and ACEIs)

Adenosine

Studies have demonstrated a functional link between adenosine and the vagal nerve activity [69]. Our study also demonstrated a possible functional interaction between muscarinic M2 receptors and α1 adenosine receptors in the I/R myocardium, and nitric oxide synthase may be the link between these two types of receptors [101]. Interestingly, adenosine has beneficial effects on M2 receptors, thus playing a role in the improvement of cardiac function. These results have demonstrated a possible new mechanism for the cardioprotection provided by adenosine. The precursor of adenosine (adenine sulfate) has also been suggested to have cardioprotective effects by increasing the expression of M2 receptors and cholinergic nerve density [102]. A recent study suggested that the inhibitory effects of VNS on HR and BP are partly mediated by endogenous adenosine release [103].

Statins

Statins, the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, is used routinely in coronary artery disease for its lipid-lowering effect. Evidence has indicated that the pleiotropic effects of statins may be involved in improving endothelial function, inhibiting inflammation and oxidative stress, attenuating myocardial remodeling, and stabilizing atherosclerotic plaques [104]. Our previous study demonstrated that atorvastatin enhances serum ACh levels and baroreflex sensitivity in I/R injury in rats [70]. In a human study, atorvastatin also had a beneficial impact on vagal activity, as measured by improvements in HRV, and might reduce the risk for arrhythmias in HF patients [105]. A recent study suggested that statins might reduce arrhythmias and improve HRV in healthy persons after 48 h of sleep deprivation [106]. The ejection fraction of HF patients without ischemic heart disease is preserved by statins [107]. However, the details of the underlying mechanisms of the effects of statins on cholinergic systems are still not fully clarified.

β-Adrenoceptor Blockers

β-Blockers improve the prognoses of patients with HF. However, their protective effect is not fully dependent on the direct blockade of sympathetic activity. The sympathetic–parasympathetic interaction plays an important role in many cardiovascular diseases. The afferent sympathetic excitation results in activation of sympathetic efferent activity, together with the inhibition of vagal activity. These phenomena are antagonized by β-blockers [22]. β-ARs include three subtypes (β1, β2, and β3) [108]. Among them, β1 is primarily expressed in the heart. The cardiovascular protective effects exerted by β-blockers are due primarily to inhibition of the M2 receptor [109]. A previous study showed that carvedilol (an α- and β-blocker) increases the expression of M2 receptors in myocardium injured by adriamycin, implying that the up-regulation of these muscarinic receptors may be partly responsible for the protective effects of carvedilol in HF [71]. It has also been reported that long-term treatment with carvedilol restores autonomic tone and responsiveness in patients with moderate HF [110]. Vagal activation induced by metoprolol, another β-blocker, prevents ventricular fibrillation in mice with dilated cardiomyopathy [111].

Angiotensin-Converting-Enzyme Inhibitors

Ramipril, an ACEI, increases HRV and cardiac function in patients with renal failure [112]. A recent study has also demonstrated that enalapril, combined with aerobic physical training, increases vagal tone [72]. In addition, delapril improves the sympatoh–vagal balance and reduces atrioventricular blocks and ventricular arrhythmia [113]. Therefore, ACEIs might be a promising type of vagomimetic drug for the treatment of cardiovascular disease; however, clarifying the potential mechanism requires more studies.

Conclusion

In this review, we have provided an overview of recent studies on the drug targets and vagomimetic drugs for vagus nerve activation in the treatment of cardiovascular disease (Table 1). This review shows that there has been a surge of data to suggest that decreased vagal activity is closely associated with the development of cardiovascular diseases and poor clinical outcomes. Targeting the vagus may be a promising therapeutic approach for the treatment of cardiovascular disease. Some vagomimetic drugs have been developed for the activation of vagal activity in cardiovascular diseases. The cardiovascular protective effects of these vagomimetic drugs may be predominantly correlated with a decrease in inflammation, the prevention of Ca2+ overload and the inhibition of RAS by improving vagal activity. The drugs discussed in this review all target vagal activation in cardiovascular diseases. Further study of these drug targets may help us to understand the mechanisms underlying vagal activation in these diseases.
Acknowledgements This review was supported by grants from the National Natural Science Foundation of China (81770293 and 81473203).

Compliance with ethical standard

Conflict of interest The authors confirm no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Bonaz B, Sinniger V, Pellissier S. Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. J Physiol 2016, 594: 5781–5790.
2. Abboud FM, Benson CJ. ASICs and cardiovascular homeostasis. Neuropharmacology 2015, 94: 87–98.
3. Arslan M, Yesilcan N, Aydin D, Yüksel R, Dane S. Wet cupping therapy restores sympathovagal imbalances in cardiac rhythm. J Altern Complement Med 2014, 20: 318–321.
4. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res 2014, 114: 1804–1814.
5. La Rovere MT, Christensen JH. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs. Vascul Pharmacol 2015, 71: 1–10.
6. Zhao M, He X, Bi XY, Yu XJ, Gil Wier W, Zang WJ. Vagal stimulation triggers peripheral vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion. Basic Res Cardiol 2013, 108: 345.
7. Lu XZ, Bi XY, He X, Zhao M, Xu M, Yu XJ, et al. Activation of M3 cholinoreceptors attenuates vascular injury after ischaemia/reperfusion by inhibiting the Ca2+/calmodulin-dependent protein kinase II pathway. Br J Pharmacol 2015, 172: 5619–5633.
8. Petkovich BW, Vega J, Thomas S. Vagal modulation of heart rate variability. Curr Hypertens Rep 2015, 17: 532.
9. Masaki I, Keichi F. Cardiac innervation and sudden cardiac death. Circ Res 2015, 116: 2005–2019.
10. Brandenberger G, Viola AU. Autonomic Nervous System Activity during Sleep in Humans. Springer, US: 2006.
11. Zhang DY, Anderson AS. The sympathetic nervous system and heart failure. Cardiol Clin 2014, 32: 33–45.

Table 1 Drugs used in vagal nerve activation and potential mechanisms.

| Classification | Drug       | Mechanism                                      | References               |
|----------------|------------|------------------------------------------------|--------------------------|
| Cholinergic drugs | Choline     | Increase of ACh levels                         | Liu, et al. 2017 [16]    |
|                 |            | α7nAChR agonist                               | Lu, et al. 2015 [7]      |
|                 |            | M3 agonist                                    | Zhao, et al. 2010 [77]   |
|                 |            | Inhibition of CaMKII and calcineurin          | Wang, et al. 2012 [75]   |
|                 |            | Inhibition of ROS                             |                          |
| ACh             |            | Down-regulation of AT1 receptor               | Liu, et al. 2011 [79]    |
|                 |            | Inhibition of ER stress                       | Bi, et al. 2015 [82]     |
|                 |            | Inhibition of UPRmt                           | Xu, et al. 2016 [83]     |
|                 |            | Inhibition of Ca2+ overload                   | He, et al. 2015 [84]     |
|                 |            | M2/M3 agonist                                 | Zhao, et al. 2017 [85]   |
| AChE inhibitors  | Pyridostigmine | AChE inhibition                               | Lataro, et al. 2015 [90] |
|                 | Donepezil   | Anti-inflammation                             | Durand, et al. 2014 [91] |
|                 |            |                                               | Gavioli, et al. 2014 [92]|
|                 |            |                                               | Lu, et al. 2017 [27]     |
|                 |            |                                               | Lu, et al. 2018 [100]    |
| Nucleoside      | Adenosine   | Enhancement of cholinergic nerve density.      | da Silva, et al. 2012 [69]|
|                 |            | Increase of M2 receptor expression            | Sun, et al. 2011[101]    |
|                 |            |                                               | Jammes, et al. 2015 [103]|
| Statins         | Simvastatin | Improvement of HRV                            | Millar, et al. 2014 [104]|
|                 | Atorvastatin | Decrease of QT variability                    | Bi, et al. 2013 [70]     |
| β-blockers       | Carvedilol  | Increase of M2 receptor expression            | Xu, et al. 2006 [71]     |
|                 | Metoprolol  | improvement of HRV                            | Zhan, et al. 2009 [111]  |
| ACEIs           | Ramipril    | Increase of HRV, cardiac function             | Maida, et al. 2016 [72]  |
|                 | Enalapril   | Inhibition of RAS activation                  | Thireau, et al. 2015 [113]|
|                 | Delapril    | Inhibition of Ca2+ overload                   |                          |

ACh, acetylcholine; AChE, acetylcholine esterase; CaMKII, Ca2+/calmodulin-dependent protein kinase II; ER, endoplasmic reticulum; HRV, heart rate variability; RAS, renin-angiotensin-system; ROS, reactive oxygen species; UPRmt, mitochondrial unfolded protein response.
12. Dyavanapalli J, Dergacheva O, Wang X, Mendelowitz D. Parasympathetic vagal control of cardiac function. Curr Hypertens Rep 2016, 18: 22.

13. Pituzalis MV. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001, 103: 2072–2077.

14. Klippel BF, Duemke LB, Leal MA, Friques AG, Dantas EM, Dalvi RF, et al. Effects of Kefir on the cardiac autonomic tones and baroreflex sensitivity in spontaneously hypertensive rats. Front Physiol 2016, 7: 211.

15. Gao J, Zucker IH, Gao L. Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure. Am J Hypertens 2014, 27: 1248–1256.

16. Liu L, Lu Y, Bi X, Xu M, Yu X, Xue R, et al. Choline ameliorates cardiovascular damage by improving vagal activity and inhibiting the inflammatory response in spontaneously hypertensive rats. Sci Rep 2017, 7: 42553.

17. Qin F, Lu Y, He X, Zhao M, Bi X, Yu X, et al. Pyridostigmine prevents peripheral vascular endothelial dysfunction in rats with myocardial infarction. Clin Exp Pharmacol Physiol 2014, 41: 202–209.

18. Rudas L, Crossman AA, Morillo CA, Halliwill JR, Tahvanainen KU, Kuusela TA, et al. Human sympathetic and vagal baroreflex responses to sequential nitroprusside and phenylephrine. Am J Physiol 1999, 276: 1691–1698.

19. Jarczok MN, Koenig J, Shively CA, Thayer JF. Behavioral depression is associated with increased vagally mediated heart rate variability in adult female cynomolgus monkeys (Macaca fascicularis). Int J Psychophysiol 2018, 131: 139–143.

20. Liu H, Yang Z, Meng F, Huang L, Qu W, Hao H, et al. Chronic vagus nerve stimulation reverses heart rhythm complexity in patients with drug-resistant epilepsy: An assessment with multiscale entropy analysis. Epilepsy Behav 2018, 83: 168–174.

21. Setty AB, Vaughn BV, Quint SR, Robertson KR, Messenheimer JA. Heart period variability during vagal nerve stimulation. Seizure 1998, 7: 213–217.

22. Schwartz PJ, De Ferrari GM. Sympathetic–parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 2010, 16: 101–107.

23. Tarallo ZZ, Terziyski KV, Kostianev SS. Heart rate variability as a method for assessment of the autonomic nervous system and baroreflex sensitivity in myocardial infarction-heart failure model. Cardiovasc Pathol 2016, 26: 21–29.

24. Wang X, Yeo PI, Naveau D, Perrotta M, Pallante F, Fardella V, Iacobucci R, Fardella S, et al. A cholinergic-sympathetic pathway primes conditions. Folia Med (Plovdiv) 2015, 57: 173–180.

25. Wang YH, Hu H, Wang SP, Tian ZJ, Zhang QJ, Li QX, et al. Exercise benefits cardiovascular health in hyperlipidemia rats correlating with changes of the cardiac vagus nerve. Eur J Appl Physiol 2010, 108: 459–468.

26. Machado BH, Brody MJ. Contribution of neurogenic mechanisms to control of intrinsic heart rate. Am J Physiol 1989, 256: 231–235.

27. Calume F, Westenbroek RE, Cheah CS, Yu FH, Oakley JC, Scheuer T, et al. Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Investig 2013, 123: 1798–1808.

28. Lu Y, Zhao M, Liu JJ, He X, Yu XJ, Liu LZ, et al. Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signaling. J Cell Mol Med 2017, 21: 2106–2116.

29. Bhattacharya A, Dunlap ME. Autonomic dysregulation as a therapeutic target for acute HF. Curr Treat Options Cardiovasc Med 2015, 17: 1–12.

30. Cauley E, Wang X, Dyavanapalli J, Sun K, Garrott K, Kuzmiak-Glancy S, et al. Neurotransmission to parasympathetic cardiac vagal neurons in the brain stem is altered with left ventricular hypertrophy-induced heart failure. Am J Physiol Heart Circ Physiol 2015, 309: H1281–1287.

31. Nederend I, Ejc DG, Ljm K, Jjm W, Blom NA, Adj TH. Cardiac autonomic nervous system activity and cardiac function in children after coarctation repair. Ann Thorac Surg 2018, 105: 1803–1808.

32. Wang J, Tipton M, Shattock MJ. Autonomic conflict exacerbates long QT associated ventricular arrhythmia. J Mol Cell Cardiol 2018, 116: 145–154.

33. Xu XL, Zang WJ, Kang XQ, Li M, Yu XJ, Chen LN, et al. Comparison of distribution of cholinergic nerves and M2 receptors between rat atria and ventricles. Nan Fang Yi Ke Da Xue Xue Bao 2006, 26: 1096–1100.

34. Inagaki M, Kawada T, Lie M, Zheng C, Sunagawa K, Sugimachi M. Intravascular parasympathetic cardiac nerve stimulation prevents ventricular arrhythmias during acute myocardial ischemia. Conf Proc IEEE Eng Med Biol Soc 2005, 7: 7076–7079.

35. Kalume F, Westenbroek RE, Cheah CS, Yu FH, Oakley JC, Scheuer T, et al. Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Investig 2013, 123: 1798–1808.

36. Wang S, Han HM, Jiang YN, Wang C, Song HX, Pan ZY, et al. Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischemia-induced arrhythmias. Clin Exp Pharmacol Physiol 2012, 39: 299–316.
46. Krejci A, Tucek S. Quantitation of mRNAs for M(1) to M(5) subtypes of muscarinic receptors in rat heart and brain cortex. Mol Pharmacol 2002, 61: 1267–1272.

47. Li DL, Liu JJ, Liu BH, Hu H, Sun L, Miao Y, et al. Acetylcholine inhibits hypoxia-induced tumor necrosis factor-α production via regulation of MAPKs phosphorylation in cardiomyocytes. J Cell Physiol 2011, 226: 1052–1059.

48. Miao Y, Zhou J, Zhao M, Liu J, Sun L, Yu X, et al. Acetylcholine attenuates hypoxia/reoxygenation-induced mitochondrial and cytosolic ROS formation in H9c2 cells via M2 acetylcholine receptor. Cell Physiol Biochem 2013, 31: 189–198.

49. Patanè S. M3 muscarinic acetylcholine receptor in cardiology and oncology. Int J Cardiol 2014, 177: 646–649.

50. Hang PZ, Zhao J, Qi JC, Wang Y, Wu JW, Du ZM. Novel insights into the pervasive role of M3 muscarinic receptor in cardiac diseases. Curr Drug Targets 2013, 14: 372–377.

51. Liu Y, Wang S, Wang C, Song H, Han H, Hang P, et al. Upregulation of M3 muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II. J Transl Med 2013, 11: 209.

52. Xue RQ, Sun L, Yu XJ, Li DL, Zang WJ. Vagal nerve stimulation improves mitochondrial dynamics via an M3 receptor/CaMKKβ/AMPK pathway in isoprotorenol-induced myocardial ischaemia. J Cell Mol Med 2017, 21: 58–71.

53. Liu Y, Sun L, Pan Z, Bai Y, Wang N, Zhao J, et al. Overexpression of M3 muscarinic receptor is a novel strategy for preventing sudden cardiac death in transgenic mice. Mol Med 2011, 17: 1179–1187.

54. Oz M, Lorke A, Krejci A, Tucek S. Pharmacological Modulation of Vagal Nerve Activity in Cardiovascular Diseases 165

55. Liu Y, Wang S, Wang C, Song H, Han H, Hang P, et al. Activation of a7 nicotinic acetylcholine receptors prevents monosodium iodoacetate-induced osteoarthritis in rats. Cell Physiol Biochem 2015, 35: 627–638.

56. de Jonge WJ, van der Zanded EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005, 6: 844–851.

57. Lu B, Kwan K, Levine YA, Olofsson PS, Yang H, Li J, et al. Seven nicotinic acetylcholine receptor signaling inhibits ischaemia–reperfusion injury in transgenic mice by preventing mitochondrial DNA release. Molecular Medicine 2014, 20: 350–358.

58. Vida G, Peña G, Deitch EA, Unloa L. α7–cholinergic receptor mediates vagal induction of splenic norepinephrine. J Immunol 2011, 186: 4340–4346.

59. Vida G, Peña G, Kanashiro A, Thompson-Bonilla MR, Palange D, Deitch EA, et al. β2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. FASEB J 2011, 25: 4476–4485.

60. Rosasballina M, Olofsson PS, Ochani M, Valdesferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011, 334: 98–101.

61. Reardon C. Neuro-immune interactions in the cholinergic anti-inflammatory reflex. Immuno Lett 2016, 178: 92–96.

62. Huang J, Qian J, Yao W, Wang N, Zhang Z, Cao C, et al. Vagus nerve stimulation reverses ventricular electrophysiological changes induced by hypersympathetic nerve activity. Exp Physiol 2015, 100: 239–248.

63. Liu JJ, Li DL, Liu BH, Hu H, Sun L, Miao Y, et al. Effect of renal sympathetic denervation on ventricular and neural remodeling. Herz 2018. https://doi.org/10.1007/s00059-018-4698-y.

64. He X, Zhao M, Bi X, Sun L, Yu X, Zhao M, et al. Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol 2015, 172: 5489–5500.

65. Acetylcholine inhibits angiotensin II-induced oxidative stress in the endothelium of adriamycin-induced rat failing heart. Auton Neurosci 2006, 130: 6–16.

66. Maida KD, Vieira S, Gasteida AC, Bezerra VB, De Araujo JE, de Souza HC. Amlodipine and enalapril promote distinct effects on cardiovascular autonomic control in spontaneously hypertensive rats: the role of aerobic physical training. J Hypertens 2016, 34: 2383–2392.

67. Zeisel SH. A brief history of choline. Ann Nutr Metab 2012, 61: 254–258.

68. Liu Y, Sun HL, Li DL, Wang LY, Gao Y, Wang YP, et al. Acetylcholine produces antiarrhythmic actions in animal models by cardiac M3 receptors: improvement of intracellular Ca2+ handling as a common mechanism. Can J Physiol Pharmacol 2008, 86: 860–865.

69. Wang S, Han HM, Pan ZW, Hang PZ, Sun LH, Jiang YN, et al. Acetylcholine inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. Naunyn Schmiedebergs Arch Pharmacol 2012, 385: 823–831.

70. Zhao Y, Wang C, Wu J, Wang Y, Zhu W, Zhang Y, et al. Choline protects against cardiac hypertrophy induced by increased after-load. Int J Mol Sci 2013, 9: 295–302.

71. Zhao J, Su Y, Zhang Y, Pan Z, Yang L, Chen X, et al. Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up-regulating cyclooxygenase-2 expression. Br J Pharmacol 2010, 159: 1217–1225.

72. Kruse AC, Kobilka BK, Gartman D, Sexton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 2014, 13: 549–560.

73. Liu JJ, Li DL, Zhou J, Sun L, Zhao M, Kong SS, et al. Acetylcholine prevents angiotensin-II-induced oxidative stress and apoptosis in H9c2 cells. Apoptosis 2011, 16: 94–103.

74. Sun L, Zhao M, Yu XJ, Wang H, He X, Liu JK, et al. Cardioprotection by acetylcholine: A novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway. J Cell Physiol 2013, 228: 1238–1248.

75. Zhao M, Sun L, Yu XJ, Miao Y, Liu JJ, Wang H, et al. Acetylcholine mediates AMPK-dependent autophagic cytoprotection in H9c2 cells during hypoxia/reoxygenation injury. Cell Physiol Biochem 2013, 32: 601–613.

76. Bi X, He X, Xu M, Zhao M, Yu X, Lu X, et al. Acetylcholine ameliorates endoplasmic reticulum stress in endothelial cells
after hypoxia/reoxygenation via M3 AChR-AMPK signaling. Cell Cycle 2015, 14: 2461–2472.

83. Xu M, Bi XY, He X, Yu XJ, Zhao M, Zang WJ. Inhibition of the mitochondrial unfolded protein response by acetylcholine alleviated hypoxia/reoxygenation-induced apoptosis of endothelial cells. Cell Cycle 2016, 15: 1331–1343.

84. He X, Bi XY, Lu XZ, Zhao M, Yu XJ, Sun L, et al. Reduction of mitochondria-endoplasmic reticulum interactions by acetylcholine protects human umbilical vein endothelial cells from hypoxia/reoxygenation injury. Arterioscler Thromb Vasc Biol 2015, 35: 1623–1634.

85. Zhao M, Jia HH, Liu LZ, Bi XY, Xu M, Yu XJ, et al. Acetylcholine attenuated TNF-α-induced intracellular Ca2+ overload by inhibiting the formation of the NCX1-TRPC3-IP3R1 complex in human umbilical vein endothelial cells. J Mol Cell Cardiol 2017, 107: 1–12.

86. Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart 2003, 89: 854–858.

87. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Invest 2011, 31: 691–701.

88. Souza AC, Grabeguimaraes A, Souza J, Botacim WE, Almeida CM. Increase in parasympathetic tone by pyridostigmine restores cardiac autonomic balance, et al. J Pharmacol Sci 2011, 104: R908–R916.

89. Wang X, Yu X, Vaughan W, Liu M, Guan Y. Novel drug-delivery approaches to the blood-brain barrier. Neurosci Bull 2015, 31: 257–264.

90. Lataro RM, Silva CA, Jr FR, Rossi MA, Prado CM, Godinho RO, et al. Improvement of vagal activity in patients receiving haemodialysis. Nephrology (Carlton) 2006, 11: 684–690.

91. Durand MT, Becari C, De OM, do Carmo JM, Silva CA, Prado CM, et al. Pyridostigmine restores cardiac autonomic balance after small myocardial infarction in mice. PLoS One 2014, 9: e104476.

92. Gavioli M, Lara A, Almeida PW, Lima AM, Damasceno DD, Sirvente R, Mostarda C, et al. Pyridostigmine protects against cardiomyopathy associated with adipose tissue browning and improvement of vagal activity in high-fat diet rats. Biochem Biophys Acta 2018, 1864: 1037–1050.

93. Lataro RM, Silva CA, de La Fuente RN, Rodrigues B, Moraes-Silva IC, Souza LE, et al. Pyridostigmine protects against cardiomyopathy associated with adipose tissue browning and improvement of vagal activity in high-fat diet rats. Biochem Biophys Acta 2018, 1864: 1037–1050.

94. Sun L, Li DL, Zhao M, He X, Yu XJ, Miao Y, et al. The role of muscarinic receptors in the beneficial effects of adenosine against myocardial reperfusion injury in rats. PLoS One 2011, 6: e25618.

95. Chen WR, Liu HB, Sha Y, Shi Y, Wang H, Yin DW, et al. Effects of statin on arrhythmia and heart rate variability in healthy persons with 48-hour sleep deprivation. J Am Heart Assoc 2016, 5: e003833.

96. Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. Int J Cardiol 2018, 255: 111–117.

97. Wallukat G. The β-Adrenergic Receptors. Herz 2002, 27: 683–690.

98. Jahns R, Boivin V, Lohse MJ. Beta 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 2006, 112: 7–14.

99. Malfatto G, Facchini M, Branzi G, Riva B, Sala L, Perego GB. Long-term treatment with the beta-blocker carvedilol restores autonomic tone and responsiveness in patients with moderate heart failure. J Cardiovasc Pharmacol 2003, 42: 125–131.

100. Zhou DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A, et al. Therapeutic effect of [beta]-adrenoceptor blockers on patients receiving haemodialysis. Nephrology (Carlton) 2006, 11: 497–501.

101. Zhan DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A, et al. Therapeutic effect of [beta]-adrenoceptor blockers on patients receiving haemodialysis. Nephrology (Carlton) 2006, 11: 497–501.

102. Zhan DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A, et al. Therapeutic effect of [beta]-adrenoceptor blockers on patients receiving haemodialysis. Nephrology (Carlton) 2006, 11: 497–501.

103. Zhan DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A, et al. Therapeutic effect of [beta]-adrenoceptor blockers on patients receiving haemodialysis. Nephrology (Carlton) 2006, 11: 497–501.